Source: International Congress 2015 – Interstitial lung diseases II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Yubiao Guo (Guangzhou, Guangdong Province, China), YuBiao Guo, Yifeng Luo, Daiyin Cao, Jingyu Chen. Expression of macrophage migration inhibitory factor in patients with idiopathic pulmonary fibrosis. Eur Respir J 2015; 46: Suppl. 59, 3849

Member's Comments

No comment yet.

Related content which might interest you: MiR-185/AKT and miR-29a/collagen 1a pathways are activated in IPF alveolar macrophages Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 The RANKL-OPG balance in pulmonary fibrosis Source: International Congress 2015 – Connective tissue disorders Year: 2015 Role of macrophage activation in type II alveolar cells transplantation for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Role of MUC1 in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Neutrophil chemotaxis and adhesion in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2001; 18: Suppl. 33, 108s Year: 2001 Pathogenesis of idiopathic pulmonary fibrosis: role of neutrophil inflammation Source: Eur Respir J 2006; 28: Suppl. 50, 102s Year: 2006 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Tranilast inhibits pulmonary fibrosis by suppressing TGFbeta-mediated extracellular matrix protein production Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Role of Bcl-xL in hepatocyte growth factor elicited epithelial protection in idiopathic lung fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis Year: 2013 Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Pulmonary expression of alternatively spliced tissue factor as a potential prognostic marker in idiopathic pulmonary fibrosis Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis? Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Role of IL-11 in vascular function of pulmonary fibrosis patients Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Role of interleukin-10 in idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 179-180 Year: 2004 Modulation of fibroblast phenotype in idiopathic pulmonary fibrosis: Role of Nrf2 Source: Annual Congress 2011 - Experimental models and research in diffuse parenchymal lung diseases Year: 2011 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Role of midkine in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Immunoproteasome expression in pulmonary fibrosis Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Pirfenidone suppresses proinflammatory and antiangiogenetic cytokine production by alveolar macrophages (AMs) in idiopathic non specific interstitial pneumonia (iNSIP) Source: International Congress 2014 – ILDs 2 Year: 2014